NCT06161376View on ClinicalTrials.gov

Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis

Not yet recruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Multiple Sclerosis
Interventions
OTHER

S1P level

Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT06161376 - Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis | Biotech Hunter | Biotech Hunter